New data shed light on the best strategies for managing patients who develop interstitial lung disease while being treated ...

June 02, 2025--(BUSINESS WIRE)--Positive results from the DESTINY-Breast09 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated a highly statistically ...

Dr. Sara M. Tolaney breaks down key takeaways from the DESTINY-Breast09 trial that patients with HER2+ advanced or metastatic ...

Confirmed objective response rate (ORR) with ENHERTU plus pertuzumab was ... the DESTINY-Breast09 results show trastuzumab deruxtecan combined with pertuzumab has the potential to become a new ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

June 02, 2025--(BUSINESS WIRE)--Positive results from the DESTINY-Breast09 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated a highly statistically ...

"As early participants in these innovative drug reimbursement processes, AstraZeneca and Daiichi Sankyo are pleased to accelerate access to innovative treatments for Canadian patients ...

Confirmed objective response rate (ORR) with ENHERTU plus pertuzumab was 85.1% versus 78. ... the DESTINY-Breast09 results show trastuzumab deruxtecan combined with pertuzumab has the potential to ...

1,2 ENHERTU (trastuzumab deruxtecan) is a HER2-directed antibody-drug conjugate. Designed using Daiichi Sankyo's proprietary DXd antibody drug conjugate (ADC) technology, ENHERTU consists of a ...